+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a phase III randomized trial comparing standard care treatment alone to standard care plus Stereotactic Ablative Radiotherapy SABR for patients with up to 10 oligometastases and a synchronous primary tumor. Patients are assigned in a 12 ratio to either receive palliative radiotherapy or a combination of standard care and SABR. Participants are stratified based on cancer histology and number of metastases to better understand treatment outcomes. The trial includes two groups the standard arm receiving palliative radiotherapy aimed at symptom relief or preventing complications, and the experimental arm receiving treatment to both the primary tumor and metastases, with SABR preferred but other options like surgery, radiofrequency ablation, or fractionated radiation allowed if deemed better by oncologists. SABR doses typically range from 20 Gy in 1 fraction to 35 Gy in 5 fractions. Chemotherapy, hormone therapy, immunotherapy, targeted systemic therapy, or observation follow standard care approaches. Participants will undergo restaging imaging, performance status assessments, and monitoring for adverse effects over approximately six years. Researchers will measure overall survival as the primary outcome, with secondary outcomes including quality of life evaluations using FACT-G and EQ-5D-5L questionnaires, toxicity assessments by CTCAE, time to next systemic therapy, and receipt of additional radiation. Safety follow-up and detailed quality of life data collection take place mainly during the first two years of the study.

Age: 18Years +All GendersPhase 3
5 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
P

Actively Recruiting

Researchers are evaluating de-escalated adjuvant treatment approaches in patients with early-stage endometrial cancer that have either POLE mutations or p53 wildtypeno specific molecular profile NSMP. The study compares new tailored treatments against the usual care, which typically involves surgery followed by analysis of tissue to determine the need for additional radiation or chemotherapy. This phase II trial aims to better understand treatment outcomes based on tumor molecular status. Participants may be enrolled in one of two sub-studies EN10.ARAINBO BLUE for POLE-mutated endometrial cancer and EN10.BTAPER for p53 wildtypeNSMP endometrial cancer. Treatments studied include observation alone, observation with adjuvant radiotherapy using external beam radiation or vaginal brachytherapy delivered through specific devices, and other standard radiation methods. These treatments are delivered following surgical removal of the uterus and ovaries, with treatment starting within 10 weeks post-surgery. During the study, participants will be monitored for pelvic, vaginal, para-aortic, and distant recurrences over a three-year period, as well as survival outcomes up to nine years. Researchers will also assess the impact of molecular classification on fear of cancer recurrence using patient-reported questionnaires. Participants will be followed closely at participating centers through scheduled visits and assessments to track treatment effects and safety throughout the study duration.

Age: 18Years +FEMALEPhase 2
123 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
A

Actively Recruiting

This research aims to understand whether patients involved in clinical trials are willing to provide information about social, economic, and environmental factors that affect their health experiences and access to care. These factors, known as social determinants of health, include income, education, employment, housing, social supports, and experiences with discrimination or stress. The study is sponsored by the Canadian Cancer Trials Group and focuses on participants related to cancer clinical trials. Participants will be asked to complete a standardized Social Determinants of Health SDoH Questionnaire in English or French, which collects detailed sociodemographic data. This questionnaire covers the conditions and places where participants live, learn, work, and play, as well as their feelings about answering such questions. The study involves both participants being screened for CCTG trials and those already enrolled and under follow-up in ongoing trials. Participation takes about 10 minutes or less. Researchers will evaluate how feasible it is to collect these comprehensive sociodemographic data and how acceptable the questionnaire is to participants over a 12-month period. The main outcome is the completion and willingness to provide this information. This observational study does not include any treatment, and participants usual care continues as normal throughout the study period.

Age: 18Years +All Genders
15 locations
O

Actively Recruiting

Researchers are evaluating the safety of omitting adjuvant whole breast radiation therapy WBRT in women with breast cancer who have no clinical lymph node involvement and have achieved a complete pathological response after neoadjuvant chemotherapy. This prospective, multi-center, single arm cohort study focuses on women with newly diagnosed T1-3 node negative breast cancer treated with breast conserving surgery and axillary staging. The study aims to observe breast tumor recurrence and survival outcomes over a median 5-year follow-up period. Participants will not receive the standard adjuvant WBRT after surgery. Instead, they will be closely monitored for any recurrence or progression of breast cancer. The study includes women who have undergone a minimum of eight weeks of neoadjuvant chemotherapy, breast conserving surgery with complete tumor bed excision, and axillary staging surgery. The absence of residual invasive or in situ cancer pathological complete response in the breast and lymph nodes is required for enrollment. During the study, participants will be followed regularly to assess ipsilateral breast tumor recurrence, local and regional recurrence, distant recurrence, disease-free survival, and overall survival. Any additional treatments received for recurrence such as repeat surgery, systemic therapy, or radiation will be documented. The total study duration extends up to five years from enrollment, with researchers evaluating tumor recurrence as the primary outcome at the median five-year mark.

Age: 50Years +FEMALE
27 locations
R

Actively Recruiting

The trial investigates the impact of a laboratory test overuse intervention bundle on reducing unnecessary lab tests among adult hospitalized medical patients in 16 hospitals across British Columbia. This stepped-wedge cluster randomized study aims to assess whether educational and patient engagement tools can effectively decrease overuse of routine lab tests such as complete blood count, electrolytes, creatinine, and coagulation tests. The study addresses concerns like patient discomfort, sleep disruption, and hospital-acquired anemia caused by excess testing. The intervention group will receive a bundle including online educational modules, clinical decision support tools, audit and feedback reports for healthcare providers, and patient engagement materials like videos and infographics. Local hospital teams will adapt and implement these tools over sequential 12-week steps, with an initial 4-week period for piloting and adapting tools followed by 8 weeks of active intervention. The control periods involve usual care without the intervention tools. Participants include hospitalized adult general medical patients under internal or family medicine care, their attending physicians, learners, and allied health staff involved in ordering tests. Researchers will collect data for at least 24 weeks after implementation to evaluate changes in laboratory test utilization, readmission rates, mortality, and related costs. The study uses monitoring of test ordering patterns, readiness assessments, and workflow observations to measure impact and sustainability without dedicated personnel support.

Age: 18Years +All GendersPhase Not Applicable
4 locations
C

Actively Recruiting

Researchers are comparing two approaches for Partial Breast Irradiation PBI used after lumpectomy in early-stage breast cancer patients. This study evaluates single fraction SF PBI, where radiation is given in one session, versus multiple fraction MF PBI, where radiation is delivered over several sessions. The aim is to understand how these methods impact quality of life, treatment side effects, and tumor control, especially to reduce travel burdens for patients in remote areas. Participants are randomly assigned to receive PBI either as 26 Gy split into 5 daily doses multiple fraction or as a single 13 Gy dose single fraction. Both treatments target the tumor bed specifically to limit radiation exposure to surrounding tissues like the lungs and heart. This study includes a two-year follow-up to compare outcomes such as local cancer control and toxicity reports. Throughout the study, participants will undergo regular assessments including quality of life questionnaires and toxicity evaluations at baseline and several times up to 24 months post-treatment. Researchers will also monitor local control rates, overall survival, and progression-free survival. The study measures how quickly treatment plans are approved and tracks any adverse events to ensure safety over the two-year period.

Age: 40Years +FEMALEPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are comparing two radiation therapy approachessingle fraction and multiple fraction stereotactic ablative radiotherapy SABRfor treating patients with 1 to 5 oligometastatic or oligo-progressive cancer lesions. This study aims to evaluate differences in treatment side effects, how long patients remain free from disease progression, quality of life, and cost-effectiveness. A subgroup will also examine the impact of healthcare provider-guided symptom management compared to questionnaire completion alone. Participants will be randomly assigned to receive either a single high-dose radiation treatment or multiple smaller doses spread over several sessions. Dosing varies by tumor location, including specific regimens for lung, bone, liver, spine, adrenal, lymph node, and brain lesions following institutional guidelines. In the subset of patients, quality of life questionnaires and symptom reporting will be used to guide healthcare interventions in one group while the other group completes questionnaires only. During the study, patients will complete quality of life assessments and symptom questionnaires at multiple time points up to five years post-treatment. Researchers will monitor adverse events, lesion control, progression-free survival, overall survival, and healthcare resource use. Radiation treatments follow a rigorous quality assurance process including CT simulation and organ contouring. The total study duration extends to approximately ten years, allowing long-term evaluation of outcomes and safety.

Age: 18Years +All GendersPhase Not Applicable
14 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Small Steps for Big Changes SSBC program, a diet and exercise counseling initiative aimed at reducing the risk of developing Type 2 Diabetes T2D among adults with prediabetes. This study partners with YMCAs across eight Canadian provinces to scale up and assess both the implementation and effectiveness of SSBC in diverse urban communities. The research focuses on how well the program is delivered and its impact on patient health outcomes over time. Participants engage in the SSBC program, which includes six sessions over four consecutive weeks. Each session offers 20 to 30 minutes of counseling to build self-regulation skills for healthy eating and exercise, followed by 20 to 30 minutes of supervised aerobic exercise. The program is delivered by YMCA community facility trainers, and participants also complete three additional exercise sessions independently. There is no randomization all enrolled individuals receive the same intervention. During the study, participants are observed for up to two years after completing the program. Researchers measure changes in diabetes status, blood sugar levels, weight, fitness, diet, and exercise habits. They also track program adoption, attendance, delivery costs, and participant satisfaction. Assessments include health questionnaires, physical measures, and healthcare resource use, helping to understand both the clinical and cost-effectiveness of SSBC over time.

Age: 18Years +All Genders
12 locations